Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27168552 | 0.80 | CYP3A4 (0.34) | CYP3A4 | |
| SCHEMBL28215938 | 0.80 | CYP3A4 (0.34) | CYP3A4 | |
| SCHEMBL28215582 | 0.80 | CYP3A4 (0.34) | CYP3A4 | |
| SCHEMBL83099 | 0.69 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL3809881 | 0.69 | — | — | |
| SCHEMBL29193898 | 0.67 | CYP3A4 (0.31) | CYP3A4 | |
| SCHEMBL7265796 | 0.67 | CYP3A4 (0.31) | CYP3A4 | |
| SCHEMBL224067 | 0.63 | CYP3A4 (0.60) | CYP3A4 | |
| SCHEMBL3714083 | 0.63 | ALDH1A1 (0.45) | CYP3A4 | |
| SCHEMBL3669277 | 0.63 | CYP3A4 (0.50) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018042460-A1 | SULPHUR CONTAINING POLYUREA FOR USE IN METAL SCAVENGING, REMOVAL AND RECOVERY | AVRA LABORATORIES PVT. LTD. (IN) | 2018-03-08 | — | — | WO | claimed |
| EP-1654055-B1 | MICROENCAPSULATED CATALYST-LIGAND SYSTEM, METHODS OF PREPARATION AND METHODS OF USE THEREOF | REAXA LTD (GB) | 2010-09-22 | — | — | EP | claimed |
| US-20090221419-A1 | Microencapsulated Catalyst-Ligand System | REAXA LIMITED (GB) | 2009-09-03 | — | — | US | claimed |
| EP-1993721-A1 | MICROENCAPSULATED CATALYST-LIGAND SYSTEM | Reaxa Limited (GB) | 2008-11-26 | — | — | EP | claimed |
| WO-2007096592-A1 | MICROENCAPSULATED CATALYST-LIGAND SYSTEM | REAXA LIMITED (GB) | 2007-08-30 | — | — | WO | claimed |
| US-20070027028-A1 | Microencapsulated catalyst-ligand system, methods of preparation and methods of use thereof | REAXA LIMITED (GB) | 2007-02-01 | — | — | US | claimed |
| EP-1654055-A1 | MICROENCAPSULATED CATALYST-LIGAND SYSTEM, METHODS OF PREPARATION AND METHODS OF USE THEREOF | Avecia Pharmaceuticals Limited (GB) | 2006-05-10 | — | — | EP | claimed |
| JP-2005511671-A | — | — | 2005-04-28 | — | — | JP | claimed |
| WO-2005016510-A1 | MICROENCAPSULATED CATALYST-LIGAND SYSTEM, METHODS OF PREPARATION AND METHODS OF USE THEREOF | REAXA LIMITED (GB) | 2005-02-24 | — | — | WO | claimed |
| US-20050010068-A1 | Use of microencapsulated transition metal reagents for reactions in supercritical fluids | AVECIA LIMITED (GB) | 2005-01-13 | — | — | US | claimed |
| US-20040254066-A1 | Dissolving or dispersion forming emulsion; transition metal catalyst encapsulated within a permeable polymer; catalyst for foirming polyol from olefin | REAXA LIMITED (GB) | 2004-12-16 | — | — | US | claimed |
| EP-1453780-A1 | THE USE OF MICROENCAPSULATED TRANSITION METAL REAGENTS FOR REACTIONS IN SUPERCRITICAL FLUIDS | Avecia Limited (GB) | 2004-09-08 | — | — | EP | claimed |
| EP-1409125-A1 | MICROENCAPSULATED CATALYST, METHODS OF PREPARATION AND METHODS OF USE THEREOF | Avecia Limited (GB) | 2004-04-21 | — | — | EP | claimed |
| WO-2003048090-A1 | THE USE OF MICROENCAPSULATED TRANSITION METAL REAGENTS FOR REACTIONS IN SUPERCRITICAL FLUIDS | AVECIA LIMITED (GB) | 2003-06-12 | — | — | WO | claimed |
| WO-2003006151-A1 | MICROENCAPSULATED CATALYST, METHODS OF PREPARATION AND METHODS OF USE THEREOF | AVECIA LIMITED (GB) | 2003-01-23 | — | — | WO | claimed |
| CN-110511345-A | A kind of mould proof antistatic aerosil polyurethane composite thermal insulation wallboard | BAI ZHONGHUA | 2019-11-29 | — | — | CN | disclosed |
| CN-110382643-A | Coating agent composition comprising PVC and plasticizing component | 巴斯夫欧洲公司 | 2019-10-25 | — | — | CN | disclosed |
| WO-2003048090-A1 | THE USE OF MICROENCAPSULATED TRANSITION METAL REAGENTS FOR REACTIONS IN SUPERCRITICAL FLUIDS | AVECIA LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003006151-A1 | MICROENCAPSULATED CATALYST, METHODS OF PREPARATION AND METHODS OF USE THEREOF | AVECIA LIMITED (GB) | 2003-01-23 | — | — | WO | disclosed |
| EP-0148769-A1 | Process for producing multiple types of microcapsules | STAUFFER CHEMICAL COMPANY (US) | 1985-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010068-A1 | Use of microencapsulated transition metal reagents for reactions in supercritical fluids | HPSE, SIK1, SGK1 | CYP3A4 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.